Clinical Trial

Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)

Study acronym: AuspiCiOus
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 2, 2024 (before its estimated May 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
To investigate the effects of the combination of two chemotherapies followed by immunostimulants on the interferon gamma expression and infiltration of cytotoxic T cells in the tumour microenvironment in patients with previously untreated metastatic or locally advanced esophagogastric cancer.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-12-15; most recent amendment 2024-08-01.
Trial Details
NCT Number NCT05177133
Lead Sponsor Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborators: Incyte Corporation
Conditions Gastric Adenocarcinoma, Esophageal Adenocarcinoma
Enrollment 25 participants
Start Date 2021-11-05
Primary Completion 2025-05-01 (estimated)
Study Completion 2029-11-04 (estimated)
Updated on ClinicalTrials.gov 2024-08-02